PEPTIDE GUIDE

What Is PE-22-28?

PE-22-28 is an experimental seven-amino-acid peptide derived from spadin, a longer peptide that blocks the TREK-1 potassium channel. Researchers developed PE-22-28 to retain that activity in a shorter molecule with stronger laboratory potency and longer effects in mice.

The principal published study reported selective TREK-1 inhibition, antidepressant-like behaviour in several mouse tests, increased formation of new hippocampal neurons and changes in a synaptic protein. These are preclinical findings. Mouse behaviour tests cannot diagnose depression or establish that a compound is an antidepressant in people.

No published human exposure, pharmacokinetic, safety or efficacy study was identifiable as of October 2026. PE-22-28 is not an approved medicine.

Research statusPreclinical TREK-1 research only; no published human exposure
Compound typeExperimental seven-amino-acid spadin fragment
Human evidenceNo published human study
ApprovalNot approved
Last reviewedOctober 2026
THE SHORT ANSWER

PE-22-28 is a synthetic heptapeptide, meaning a chain of seven amino acids, with the sequence Gly-Val-Ser-Trp-Gly-Leu-Arg. It represents residues 22 to 28 of a larger sortilin-derived peptide and is a shortened relative of spadin. In engineered cells it inhibited the TREK-1 potassium channel at very low concentrations and appeared selective against several related channels. In mice it reduced immobility and escape delay in tests used to screen possible antidepressants, while laboratory measurements suggested neurogenesis and synaptic changes. The evidence comes largely from one research programme. No clinical trial has established absorption, brain exposure, benefit, adverse effects or a human dose. Claims that PE-22-28 treats depression, anxiety or cognitive impairment are unsupported.

What kind of molecule is PE-22-28?

PE-22-28 is a linear peptide made from seven standard L-amino acids. Its sequence is:

`Gly-Val-Ser-Trp-Gly-Leu-Arg`

The numbers refer to its position within a larger peptide precursor rather than its length. PE-22-28 spans residues 22 through 28 of the 44-amino-acid peptide called PE, which is produced during processing of the protein sortilin.

The molecule is also called a shortened spadin analogue. Spadin corresponds to residues 12 through 28 of PE and therefore contains 17 amino acids. PE-22-28 is the shorter C-terminal part that retained strong TREK-1 inhibition in the published screening experiments.

It is not related to P21 or P021, the CNTF-derived peptidomimetic covered in a separate guide. Similar letters and numbers do not indicate similar chemistry or biology.

What are sortilin, PE and spadin?

Sortilin is a receptor and trafficking protein found in several tissues, including the nervous system. It helps direct proteins between cellular compartments and can participate in signalling. The SORT1 gene provides instructions for making it.

During production of sortilin, a propeptide segment is cut away. Researchers identified a 44-amino-acid circulating peptide from this region and called it PE. Spadin was designed from residues 12 to 28 of PE after experiments connected that segment with inhibition of TREK-1.

The first spadin paper, published in 2010, reported channel blockade and antidepressant-like effects in rodents. Later work found that spadin's behavioural activity after a single mouse administration diminished within several hours. PE-22-28 emerged from studying shorter blood-degradation fragments and screening which fragments retained activity.

Spadin is described as sortilin-derived, but PE-22-28 is a designed synthetic fragment. It should not be presented as a hormone or as a natural human antidepressant.

What is TREK-1?

TREK-1 is a two-pore-domain potassium channel encoded by the KCNK2 gene. Potassium channels control the movement of potassium ions across cell membranes, helping determine a neuron's electrical excitability.

TREK-1 responds to membrane stretch, temperature, acidity, fatty acids and several signalling molecules. It is present in brain regions involved in mood, pain and stress responses, but it also has functions outside any single psychiatric pathway.

Mice lacking TREK-1 showed behavioural and neurochemical features that encouraged researchers to test the channel as an antidepressant target. Blocking one channel can alter neuronal firing, but depression in people is biologically and clinically diverse. A channel mechanism cannot by itself establish treatment benefit.

How does PE-22-28 interact with TREK-1?

The 2017 study expressed human TREK-1 in HEK cells, a laboratory cell line derived from human embryonic kidney cells. Patch-clamp electrophysiology was used to measure electrical current through the channel.

PE-22-28 inhibited about 55% of TREK-1 current in a screening experiment. Its half-maximal inhibitory concentration, or IC50, was reported as approximately 0.12 nanomolar, compared with about 40 nanomolar for spadin under the study conditions. IC50 is the concentration associated with half of the measured maximum inhibition in that assay. A lower number indicates greater potency in the assay, not greater clinical effectiveness.

The researchers also tested TREK-2, TRAAK, TRESK and TASK-1, related two-pore-domain potassium channels. PE-22-28 did not produce the same inhibition at the tested concentration. It also did not measurably alter the hERG potassium current in the reported experiment. hERG is important to cardiac electrical recovery, and its blockade can contribute to dangerous rhythms.

This selectivity panel is useful but incomplete. It does not assess every ion channel, receptor, enzyme or tissue, and it cannot replace safety pharmacology in animals and people.

How was PE-22-28 developed?

PeriodDevelopment
2006Mouse genetics strengthened interest in TREK-1 as a possible antidepressant target
2010Researchers reported spadin as a sortilin-derived TREK-1 blocker with rodent behavioural effects
Mid-2010sSpadin degradation and modified analogues were investigated to improve duration and exposure
2017PE-22-28 and related short analogues were reported in cell, neuron and mouse experiments
2018 onwardReviews discussed TREK-1 blockade, while direct PE-22-28 evidence remained sparse
Current positionPreclinical research peptide with no published human development programme

The development record is concentrated in a small number of connected laboratories. Independent replication and a formal toxicology programme would be needed before a first human study.

What did the mouse behavioural tests show?

The 2017 paper used several behavioural models. In the forced-swim test, mice placed in water alternate between swimming and immobility. Compounds that reduce immobility may have antidepressant-like activity, although changes in movement, stress response or arousal can also affect the result.

After acute experimental administration, PE-22-28 reduced mean immobility from about 162 seconds in saline controls to about 92 seconds in groups of ten mice. It also reduced immobility after four days in mice exposed to corticosterone, a stress-hormone model used to create depression-related changes.

The learned-helplessness test measures escape behaviour after unavoidable stress. The novelty-suppressed-feeding test records how long a food-deprived animal takes to approach food in an unfamiliar setting. PE-22-28 and related analogues altered these measures after short experimental treatment.

These tests are screens, not miniature clinical trials. A mouse cannot report persistent low mood, guilt, suicidal thoughts or loss of interest, and a positive test does not prove efficacy in major depressive disorder.

Did PE-22-28 act faster than conventional antidepressants?

The paper reported behavioural effects after acute exposure or four days of repeated exposure. That is faster than the several weeks often required for the full clinical effect of conventional antidepressants.

The comparison is indirect. PE-22-28 was tested in mice under short experimental protocols, while the clinical time course of antidepressants is measured through human symptoms and functioning. The study did not randomise patients to PE-22-28 and an established medicine.

It is therefore accurate to say that short-duration mouse effects were reported. It is not accurate to call PE-22-28 a rapid-acting human antidepressant.

What did the neurogenesis experiments show?

Neurogenesis is the production of new neurons from precursor cells. The researchers labelled dividing cells in the hippocampus, a brain region involved in memory and stress regulation. After four days, mice exposed to PE-22-28 or selected analogues had more labelled cells than saline controls.

The study reported about 1,736 labelled cells for PE-22-28 compared with about 899 in controls, with five mice per group. Cell labelling supports increased proliferation or survival during the measurement window. It does not show that every labelled cell became a mature, integrated neuron or that the change would improve human mood.

Adult neurogenesis is only one proposed part of antidepressant biology. Depression is not simply a deficiency of new hippocampal neurons.

What did the synapse experiments show?

Mouse cortical neurons grown in culture were exposed to PE-22-28 and related analogues. Researchers measured PSD-95, a protein concentrated at excitatory synapses. The reported amount rose over 36 hours.

PSD-95 is a molecular marker associated with synaptic structure. An increase in a culture dish does not establish formation of functional brain networks, better cognition or recovery from depression. The experiment also used mouse neurons outside the living brain.

“Synaptogenesis” in the paper describes this preclinical evidence. It should not be translated into claims that PE-22-28 repairs or rewires the human brain.

How long did the reported effects last?

Some chemically modified PE-22-28 analogues retained effects in the forced-swim test for longer than spadin. The reported half-effect times ranged from about 14 to 23 hours for selected analogues, compared with roughly six hours for spadin.

These were behavioural half-effect estimates, not blood half-lives. They describe how long a mouse test result persisted under the study design. They do not reveal how much intact peptide remained in blood or brain.

Ordinary PE-22-28 and modified analogues must also be kept separate. A glycine-to-alanine substitution or an attached biotin group creates a different molecule with potentially different distribution and safety.

Does PE-22-28 cross the blood-brain barrier?

The blood-brain barrier restricts movement of many substances from blood into brain tissue. Central behavioural and cellular effects in mice suggest that relevant exposure may have occurred, but the 2017 programme did not establish human brain penetration.

Researchers explored biotinylation partly because chemical modification might increase brain uptake. Biotinylated PE-22-28 derivatives are not equivalent to the unmodified peptide.

No published human study reports oral absorption, blood concentration, cerebrospinal-fluid concentration or brain imaging after PE-22-28 exposure.

Is PE-22-28 the same as a BDNF peptide?

No. Some commercial descriptions incorrectly call it a brain-derived neurotrophic factor analogue or TrkB agonist. The published design is based on the sortilin propeptide and spadin, with TREK-1 as the principal target.

Brain-derived neurotrophic factor, shortened to BDNF, is a separate human protein that signals mainly through the TrkB receptor. Neurogenesis or PSD-95 findings do not turn PE-22-28 into BDNF.

How is PE-22-28 synthesised and characterised?

A seven-residue linear peptide can be produced by solid-phase peptide synthesis. Protected amino-acid building blocks are attached sequentially to a resin support. The completed chain is released, deprotected and purified, commonly by high-performance liquid chromatography.

Manufacturing controls need to detect deletion sequences, incomplete coupling, oxidation and other related substances. Tryptophan can be sensitive to oxidation, while the terminal arginine contributes charge and may affect handling.

Identity testing can include intact-mass spectrometry, sequence confirmation and chromatographic comparison. Peptide content, water, counterions and residual solvents are separate from chromatographic purity. A functional TREK-1 assay may be needed to confirm biological activity.

Any sterile investigational formulation would also require validated controls for sterility, bacterial endotoxin, particles, concentration, stability and container compatibility. Research-grade material is not a clinically qualified medicine.

What is known about pharmacokinetics?

No human pharmacokinetic study defines PE-22-28 absorption, distribution, metabolism, clearance or half-life. The mouse paper studied behavioural duration and compared routes within its experiments, but it did not create a human exposure model.

Small peptides can be degraded by peptidases and cleared through the kidneys. Shorter length may simplify synthesis but does not guarantee oral availability or brain delivery.

Animal administration levels are research context only. They cannot be converted into a human amount by body weight because species differ in metabolism, tissue distribution and target biology.

What is known about safety?

The main study included channel-selectivity and hERG experiments, but no published human adverse-event record exists. A limited laboratory panel cannot rule out effects on other ion channels, receptors, cardiac function, seizure threshold, movement or behaviour.

TREK-1 participates in pain, temperature sensing, anaesthesia and neuroprotection as well as mood-related pathways. Blocking it could produce effects beyond the intended mechanism. Long-term consequences of altered neurogenesis and synaptic signalling are also unknown.

A development programme would need repeat-dose toxicology, safety pharmacology, genotoxicity, reproductive assessment where relevant, immune testing and a controlled first-in-human study.

Has PE-22-28 been tested in humans?

No published human exposure study or PE-22-28-specific registered clinical trial was identifiable as of October 2026. There is no established human formulation, bioavailability, brain exposure, adverse-event profile or therapeutic effect.

This is not merely a shortage of large trials. The first clinical safety step has not been documented publicly.

Is PE-22-28 approved?

No. PE-22-28 is not approved by the FDA, MHRA or EMA for depression, anxiety, cognitive impairment or any other condition. It has no authorised product label or regulator-reviewed manufacturing specification.

How strong is the evidence overall?

QuestionBest available evidenceDefensible conclusion
Does PE-22-28 inhibit TREK-1?Engineered-cell electrophysiologyPotent inhibition was reported in one main programme
Is it selective?A small channel panelSelectivity against several related channels was reported; broader profiling is absent
Does it have antidepressant-like activity?Several mouse behavioural testsPreclinical activity was reported, not human antidepressant efficacy
Does it alter neurogenesis or synaptic markers?Mouse labelling and cultured neuronsSelected markers changed under experimental conditions
Is it safe or effective in people?No human studyUnknown
Is it approved?No regulatory approvalNo

PE-22-28 is a useful research probe for the TREK-1 hypothesis. Its narrow and largely single-programme evidence base is far from the evidence required for a psychiatric medicine.

What claims are not established?

PE-22-28 has not been shown to treat depression, anxiety, post-traumatic stress disorder, cognitive impairment or neurodegeneration in people. It has not been shown to work faster or cause fewer adverse effects than approved antidepressants.

There is no evidence-based self-administration protocol and no controlled human evidence for combining it with conventional antidepressants, ketamine, Semax, Selank or other research compounds.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

What does PE-22-28 mean?

It identifies residues 22 through 28 of the larger PE sequence derived from the sortilin propeptide.

How many amino acids does PE-22-28 contain?

Seven. Its sequence is Gly-Val-Ser-Trp-Gly-Leu-Arg.

Is PE-22-28 the same as spadin?

No. Spadin contains 17 amino acids and corresponds to PE residues 12 through 28. PE-22-28 is a shorter fragment.

What is its proposed target?

The principal reported target is TREK-1, a potassium channel involved in neuronal electrical activity.

Is PE-22-28 a BDNF analogue?

No. It is sortilin-derived and was developed through spadin research, not from brain-derived neurotrophic factor.

Does it treat depression?

Mouse tests showed antidepressant-like effects, but no human trial has tested treatment of depression.

Does it increase neurogenesis?

More labelled hippocampal cells were reported in mice. That does not establish meaningful human neurogenesis or clinical benefit.

Does it cross the blood-brain barrier?

Human brain penetration has not been measured publicly. Mouse effects do not define human delivery.

Has PE-22-28 been tested in humans?

No published human exposure study was identifiable as of October 2026.

Is PE-22-28 approved?

No. It is not an approved medicine for any indication.

Research reviewed through October 2026.